Asterand held two general meetings today – their Annual General Meeting and an extraordinary General Meeting immediately after to approve the sale of part of the business and delisting from the main LSE market. Asterand is a fully listed UK company which operates in the human tissue field. In June 2011 it had a market cap of £15m but now it’s £0.6m, and there appears to be a substantial risk that it will go into administration. To buy a US company called Bioseek, it took on substantial debt including debt obligations to the vendors. When the performance of the company declined, covenants were breached and the lenders asked for their money back (at least I believe that’s a simple summary of a rather complex story which has not been very
...Not a member? Join today
Joining ShareSoc helps to empower our collective voice in representing investors, but we also offer exclusive benefits:
Member events & Masterclasses
Regular newsletter
Member only on-line Forums / Q&As
Company data and Voting Guidance
Educational resources
Get involved in our activities
Already a member?
Log in to your account to access this content and all of your other ShareSoc membership benefits.